PROSCA & BLADDR 2022
PROSCA
PROSCA & BLADDR 2022
The Future of Prostate Cancer Pathology
FEATURING
Eva Comperat
- 124 views
- December 28, 2022
PROSCA & BLADDR 2022
The Future of External Beam Radiotherapy for Prostate Cancer
FEATURING
Alberto Bossi
- 75 views
- December 28, 2022
- 1
PROSCA & BLADDR 2022
A Medical Oncologist’s Perspective on Therapy Development in Prostate Cancer
FEATURING
Eleni Efstathiou
- 628 views
- December 28, 2022
- 2
PROSCA & BLADDR 2022
Oligorecurrent Prostate Cancer
FEATURING
Julia Murray
- 159 views
- December 28, 2022
PROSCA & BLADDR 2022
Optimal Strategies for Prostate Cancer Patients Progressing on AR-Pathway Inhibitors
FEATURING
Amit Bahl
- 115 views
- December 28, 2022
PROSCA & BLADDR 2022
PARPi in Prostate Cancer: Single Agents and Combinations
FEATURING
Elena Castro
- 137 views
- December 28, 2022
PROSCA & BLADDR 2022
Optimal Strategies for Prostate Cancer Patients Progressing on AR-Pathway Inhibitors: Radioligand Therapy
FEATURING
Ken Herrmann
- 43 views
- December 28, 2022
PROSCA & BLADDR 2022
Prostate Cancer Treatment Intensification With Chemotherapy: Does Volume Matter?
FEATURING
Silke Gillessen
- 213 views
- December 28, 2022
PROSCA & BLADDR 2022
Prostate Cancer Treatment Intensification With Radiotherapy: Does Volume Matter?
FEATURING
Nick James
- 137 views
- December 28, 2022
PROSCA & BLADDR 2022
Prostate Cancer: Managing Cardiovascular and Skeletal Comorbidities
FEATURING
Amit Bahl
- 269 views
- December 28, 2022
- 1
PROSCA & BLADDR 2022
Role of Surgery in Very High-Risk Prostate Cancer
FEATURING
Steven Joniau
- 101 views
- December 28, 2022
PROSCA & BLADDR 2022
Radiotherapy in Very High-Risk Prostate Cancer
FEATURING
Alberto Bossi
- 229 views
- December 28, 2022
- 2
PROSCA & BLADDR 2022
Systemic Treatment in High-Risk Localized Prostate Cancer
FEATURING
Karim Fizazi
- 317 views
- December 28, 2022
- 1
PROSCA & BLADDR 2022
The Added Benefit of New Imaging for (Very) High-Risk Prostate Cancer Patients: Are Bone Scan and CT Enough?
FEATURING
Anwar Padhani
- 127 views
- December 28, 2022
- 1
PROSCA & BLADDR 2022
Impact of Genomic Classifiers on Postoperative Prostate Cancer Treatment
FEATURING
Alan Dal Pra
- 41 views
- December 28, 2022
PROSCA & BLADDR 2022
DEBATE: Do We Postpone Salvage RT Until a Positive PSMA-PET/CT? Yes
FEATURING
Roderick van den Bergh
- 42 views
- December 28, 2022
PROSCA & BLADDR 2022
DEBATE: Do We Postpone Salvage RT Until a Positive PSMA-PET/CT? No
FEATURING
Julia Murray
- 56 views
- December 28, 2022
PROSCA & BLADDR 2022
Follow-Up After Radical Therapy for Prostate Cancer: Not All That Shines Is Positive
FEATURING
Karolien Goffin
- 119 views
- December 28, 2022
- 1
PROSCA & BLADDR 2022
PSMA-PET/CT-Based RT for Prostate Cancer in Salvage Setting
FEATURING
Vérane Achard
- 42 views
- December 28, 2022
PROSCA & BLADDR 2022
Genomic Risk Assessment for Active Surveillance in Prostate Cancer
FEATURING
Eric Klein
- 57 views
- December 28, 2022
PROSCA & BLADDR 2022
Management of Intermediate Risk Prostate Cancer: The Role of Imaging - Focus on MRI
FEATURING
Anwar Padhani
- 339 views
- December 28, 2022
- 1
PROSCA & BLADDR 2022
Highlights of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022
FEATURING
Aurelius Omlin,
Silke Gillessen
- 30 views
- December 28, 2022
PROSCA & BLADDR 2022
New Concepts in Prostate Cancer Pathology
FEATURING
Eva Comperat
- 73 views
- December 28, 2022
PROSCA & BLADDR 2022
Immunotherapy in Prostate Cancer
FEATURING
Aurelius Omlin
- 37 views
- December 28, 2022
PROSCA & BLADDR 2022
AR Antagonists for Prostate Cancer: Are They All Equal?
FEATURING
Bertrand Tombal
- 226 views
- December 28, 2022